» Articles » PMID: 3282641

Non-Hodgkin's Malignant Lymphomas in Patients Older Than 80. 70 Cases

Overview
Journal Cancer
Publisher Wiley
Specialty Oncology
Date 1988 May 15
PMID 3282641
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

In two centers (a comprehensive cancer center and a university hospital) 1300 patients with non-Hodgkin's lymphomas (NHL) were observed during the past 15 years. Seventy patients (5.4%) were diagnosed after they were 80 years old. Thirty-four patients had low-grade NHL, eight had intermediate grade, and 28 had high-grade NHL. The majority of them were classified as Stage I (n = 24) or II (n = 18), and the rest as Stage III (n = 16) or IV (n = 12). Treatment varied with grade of NHL, tumoral extension, and performance status. Forty-seven patients were given chemotherapy, 37 radiotherapy, and six patients had surgery. Overall, treatment was considered to be optimal in 12 patients, good in 34 patients, and limited in 24 patients. Toxicity was minimal in 62 patients, treatment-limiting in two patients, and lethal in six patients. Thirty-seven patients achieved a complete remission (CR), 21 a partial remission, five experienced stabilization, and seven failed to respond. For all patients, the median survival (MS) was 18 months. In contrast to younger patients, malignancy grade had no significant influence. The only significant parameter is CR (P = 0.02). In conclusion, very old patients must be treated correctly but carefully. Better tolerated treatments are needed to improve results that are neither very poor nor as good as in younger patients.

Citing Articles

Cure rate in the elderly patients with diffuse large B cell lymphoma deteriorates after the age of 80-results from a single-center survey.

Freudenberger F, Ohler A, Theobald M, Hess G Ann Hematol. 2021; 100(4):1013-1021.

PMID: 33634349 PMC: 7960616. DOI: 10.1007/s00277-021-04461-8.


Low-dose trofosfamide plus rituximab is an effective and safe treatment for diffuse large B-cell lymphoma of the elderly: a single center experience.

Schelker R, Herr W, Reichle A, Vogelhuber M BMC Cancer. 2018; 18(1):1000.

PMID: 30340554 PMC: 6195694. DOI: 10.1186/s12885-018-4885-5.


Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611).

Tallarico M, Foster J, Seisler D, Lafky J, Hurria A, Jatoi A J Geriatr Oncol. 2018; 9(4):321-328.

PMID: 29673807 PMC: 6015785. DOI: 10.1016/j.jgo.2018.03.018.


Palliative therapies in elderly cancer patients.

Porzsolt F, Zeeh J, Platt D Drugs Aging. 1995; 6(3):192-209.

PMID: 7542508 DOI: 10.2165/00002512-199506030-00003.


Cancer chemotherapy in the elderly: a series of 51 patients aged greater than 70 years.

Becouarn Y, Bui B, Brunet R, Ravaud A Cancer Chemother Pharmacol. 1991; 29(2):159-63.

PMID: 1760860 DOI: 10.1007/BF00687328.